title: Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement.
authors.forename: J W
authors.initials: JW
authors.lastname: Baars
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: C J
authors.initials: CJ
authors.lastname: Van Groeningen
authors.forename: J B
authors.initials: JB
authors.lastname: Vermorken
authors.forename: E M
authors.initials: EM
authors.lastname: Bijvank
authors.forename: H M
authors.initials: HM
authors.lastname: Pinedo
authors.forename: J J
authors.initials: JJ
authors.lastname: Nauta
mesh_terms: D002292:Carcinoma, Renal Cell / Q000628:therapy; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000628:therapy; D008099:Liver / Q000187:drug effects*; D008545:Melanoma / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma